nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study
|
West, H.L. |
|
|
16 |
7 |
p. 1076-1080 |
artikel |
2 |
Anxiety, depression, and quality of life in caregivers of patients with cancer in late palliative phase
|
Grov, E.K. |
|
|
16 |
7 |
p. 1185-1191 |
artikel |
3 |
A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer
|
Rea, D.W. |
|
|
16 |
7 |
p. 1123-1132 |
artikel |
4 |
A phase I–II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer
|
Aschele, C. |
|
|
16 |
7 |
p. 1140-1146 |
artikel |
5 |
A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours
|
Pico, J.-L. |
|
|
16 |
7 |
p. 1152-1159 |
artikel |
6 |
A randomized, multicenter study of subcutaneous and intravenous darbepoetin alfa for the treatment of chemotherapy-induced anemia
|
Justice, G. |
|
|
16 |
7 |
p. 1192-1198 |
artikel |
7 |
Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype
|
Orlando, L. |
|
|
16 |
7 |
p. 1094-1099 |
artikel |
8 |
Bevacizumab—current status and future directions
|
Midgley, Rachel |
|
|
16 |
7 |
p. 999-1004 |
artikel |
9 |
CAG repeat polymorphism in the DNA polymerase γ gene in a Polish population: an association with testicular cancer risk
|
Nowak, R. |
|
|
16 |
7 |
p. 1211-1212 |
artikel |
10 |
Comment on ‘Cancer genetic counselling’ by P. Mandich et al. (Ann Oncol 2005; 16: 171)
|
Contegiacomo, A. |
|
|
16 |
7 |
p. 1208-1209 |
artikel |
11 |
Communicating prognosis in cancer care: a systematic review of the literature
|
Hagerty, R.G. |
|
|
16 |
7 |
p. 1005-1053 |
artikel |
12 |
Does the concurrent use of anthracycline and granulocyte colony-stimulating factor influence the risk of secondary leukaemia in breast cancer women?
|
Di Cosimo, S. |
|
|
16 |
7 |
p. 1209-1210 |
artikel |
13 |
Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases
|
Lassau, N. |
|
|
16 |
7 |
p. 1054-1060 |
artikel |
14 |
Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients
|
Cortes-Funes, H. |
|
|
16 |
7 |
p. 1081-1086 |
artikel |
15 |
Evolving imaging technology: contrast-enhanced Doppler ultrasound is early and rapid predictor of tumour response
|
Eggermont, A.M.M. |
|
|
16 |
7 |
p. 995-996 |
artikel |
16 |
Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients
|
Schwinger, W. |
|
|
16 |
7 |
p. 1199-1206 |
artikel |
17 |
Front-line doublets in advanced non-small cell lung cancer: The golden age for second line chemotherapy
|
Besse, B. |
|
|
16 |
7 |
p. 997-998 |
artikel |
18 |
High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer
|
Mattioli, R. |
|
|
16 |
7 |
p. 1147-1151 |
artikel |
19 |
High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel and concurrent radiotherapy
|
Pasini, F. |
|
|
16 |
7 |
p. 1133-1139 |
artikel |
20 |
In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas †
|
Lacrima, K. |
|
|
16 |
7 |
p. 1169-1176 |
artikel |
21 |
Jaw avascular bone necrosis associated with long-term use of biphosphonates
|
Sanna, G. |
|
|
16 |
7 |
p. 1207-1208 |
artikel |
22 |
Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-α be better?
|
Bonvalot, S. |
|
|
16 |
7 |
p. 1061-1068 |
artikel |
23 |
Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study
|
Aravantinos, G. |
|
|
16 |
7 |
p. 1116-1122 |
artikel |
24 |
Phase I trial of liposomal encapsulated doxorubicin (Myocet™; D-99) and weekly docetaxel in advanced breast cancer patients
|
Mrózek, E. |
|
|
16 |
7 |
p. 1087-1093 |
artikel |
25 |
Prognostic significance of syndecan-1 expression in human endometrial cancer
|
Hasengaowa, |
|
|
16 |
7 |
p. 1109-1115 |
artikel |
26 |
Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma
|
Hutchings, M. |
|
|
16 |
7 |
p. 1160-1168 |
artikel |
27 |
Randomized phase III trial comparing cisplatin–etoposide to carboplatin–paclitaxel in advanced or metastatic non-small cell lung cancer
|
Belani, C.P. |
|
|
16 |
7 |
p. 1069-1075 |
artikel |
28 |
Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?
|
Jacobi, U. |
|
|
16 |
7 |
p. 1210-1211 |
artikel |
29 |
SOR guidelines for concomitant chemoradiotherapy for patients with uterine cervical cancers: evidence update bulletin 2004
|
Haie-Meder, C. |
|
|
16 |
7 |
p. 1100-1108 |
artikel |
30 |
SV40 infection in human cancers
|
Brousset, P. |
|
|
16 |
7 |
p. 1212-1213 |
artikel |
31 |
Table of Contents
|
|
|
|
16 |
7 |
p. ii-iii |
artikel |
32 |
Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme
|
Barrié, M. |
|
|
16 |
7 |
p. 1177-1184 |
artikel |